The NDA submission included data from the STRIVE-ON trial, which compared GTx-104 with oral nimodipine in patients hospitalized with aSAH.
Supported by the CHORD trial, this AAV vector-based therapy delivers a working copy of the OTOF gene and restores otoferlin protein production.
The PIONEER TEENS trial compared oral semaglutide at maximum tolerated doses with placebo in adolescents aged 10 to 17 years with T2D.
The expanded approval was based on data extrapolated from Study A, B, and C of the LIBERTY-CUPID program and supportive pharmacokinetics data from the single-arm CUPIDKids study.
"I’m not going to make that kind of commitment," replied CDC director Kennedy when asked if he'd support vaccine guidance from Dr Schwartz. HealthDay News — During a tense congressional hearing ...
A new effort to prepare for future bird flu outbreaks is moving forward, despite a major funding setback. The American pharmaceutical and biotechnology company Moderna has initiated a large clinical ...
Sources familiar with the decision who spoke to The Post anonymously said the report had passed the CDC’s scientific review before the delay.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results